CA-DIALPAD
26.10.2021 10:02:05 CEST | Business Wire | Press release
Dialpad Inc. , the industry leader in AI-powered communication and collaboration, today announced its partnership with Workair , a leading provider of business phone systems and contact center solutions in Ireland. The Dialpad-Workair partnership will empower Workair to match rising demand for cloud communications solutions with Dialpad®, the one platform for a truly unified Communications as a Service (TrueCaaS™) experience. Simple to deploy, available on any device and backed up with Voice Intelligence (Vi™) to create a searchable archive of every call, Dialpad improves communication between employees, customers, and business partners working from anywhere.
“Workair has a history of bringing the latest business phone and contact center products to Ireland. The addition of Dialpad strengthens our product portfolio with a cutting-edge cloud provider trusted by some of the most innovative companies including Uber, Stripe and WeWork,” said Stephen Mackarel, Managing Director, Workair. “Dialpad is an AI-powered cloud communications platform that covers a full range of modern business communications needs including voice, messaging, meetings, video conferencing and contact center which enables employees to collaborate securely from anywhere across any device, in a single platform. We are delighted to welcome Dialpad to Workair and to Ireland.”
Dialpad is the only provider of Unified Communications as a Service (UCaaS) and Contact Center as a Service (CCaaS) capabilities delivered from an enterprise cloud platform as a truly unified communications solution. All from one platform and one app to tap, TrueCaaS delivers enterprise-grade business communications and collaboration offerings for companies of all sizes. With a unified solution delivered through a single pane of glass with an intuitive interface, Dialpad helps customers simplify business collaboration and avoid the growing phenomenon of “app overload.” Dialpad’s products are designed for the remote workforces of today and tomorrow, presenting distributed workforces a seamless experience for productive collaboration.
“We are very excited about this partnership with Workair and look forward to bringing Dialpad’s disruptive cloud communications platform to more companies in the Irish market,” said Mike Kane, Senior Vice President, Channel Sales, Dialpad. “As Dialpad rapidly expands in the EMEA market, partnering with Workair will propel us forward and build on our momentum to exceed growth expectations.”
Additional Resources
- Discover how Dialpad utilizes AI to unify UCaaS and CCaaS
- Read more about Enova Energy’s experience with Dialpad
- Learn why Dialpad is a Major Player in the IDC MarketScape: Worldwide UCaaS Service Providers for SMB and Enterprise 2021 Vendor Assessments
Social Networks:
- Web: https://www.dialpad.com/
- Blog: https://www.dialpad.com/blog/
- Twitter: https://twitter.com/dialpadHQ/
- LinkedIn: https://www.linkedin.com/company/dialpad/
- Facebook: https://www.facebook.com/Dialpadhq/
- Instagram: https://www.instagram.com/Dialpad/
About Dialpad
Dialpad is the global leader in AI communications for business, transforming how the world works together. Dialpad customers benefit from truly unified business and customer communications, including a cloud business phone system, text and team messaging, video meetings and the world’s most advanced AI Contact Center — all in one beautiful app. More than 7,000 innovative brands and millions of people use Dialpad to connect their teams from anywhere including Motorola Solutions, Netflix, T-Mobile, Twitter, Uber and WeWork. Visit www.dialpad.com for more information and a demo.
About Workair
Founded in 2016, Workair is built on a foundation of more than 30 years of experience in communications and technology. Its business phone systems and call centre solutions offer a full-service solution that benefits management, employees and customers. Combine voice, video, messaging, integrations and analytics on a single platform, changing the way companies communicate. Workair have partnered with global leaders in the communication solutions space to provide the best system that can be tailored to suit your specific business needs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005087/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom